Data and market exclusivity prevents a generic competitor referencing the pre-clinical and clinical trial data of an authorised
reference medicinal product, for eight years, when applying for an abridged marketing authorisation. This period is followed
by two years market exclusivity before the generic product can enter the market. A further one year of market exclusivity is
possible for reference products that have a new therapeutic indication . . .
This content is restricted to subscribers. To view this content please register an account.
If you are already a subscriber, please login below.